SLC5A2 and chronic kidney disease: The identification of an expanding array of pharmacological interventions, including Renin-Angiotensin System (RAS) blockers, Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, vasopressin receptor 2 antagonists, and nonsteroidal mineralocorticoid receptor antagonists, which have been demonstrated to decelerate the advancement of CKD, represents a significant breakthrough (Zhong et al., 2015; Yang et al., 2022).